Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai CEO Haruo Naito unveiled plans to revamp the company's research and development structure in hopes of having his employees produce better results, Naito told analysts Feb. 27 in TokyoYou may also be interested in...
With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth
Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011
With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth
Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011
Zenyaku Kogyo Teams With Theraclone For Influenza Antibodies
Tokyo-based Zenyaku Kogyo is hoping Theraclone's I-STAR technology can kick-start the company's influenza vaccine development
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports